Latest period
$55.08B
YoY change
+22.6%
5Y CAGR
+90.2%
Peak year (2025)
$54.86B
Latest annual
$54.86B
Total Liabilities history chart for Novo Nordisk (NVO) from 1985 to 2025
Latest: $54.86B
Total Liabilities growth chart for Novo Nordisk (NVO) from 1985 to 2025
Latest: +22.6%
Total Liabilities history table for Novo Nordisk (NVO) from 1985 to 2025
| 2025 | $54.86B | +22.6% | +$10.11B | ||
| 2024 | $44.75B | +45.4% | +$13.96B | ||
| 2023 | $30.79B | +35.5% | +$8.07B | ||
| 2022 | $22.72B | +20.0% | +$3.78B | ||
| 2021 | $18.93B | +759.7% | +$16.73B | ||
| 2020 | $2.20B | +43.6% | +$668.90M | ||
| 2019 | $1.53B | -83.1% | −$7.52B | ||
| 2018 | $9.05B | +6.9% | +$582.06M | ||
| 2017 | $8.47B | +14.5% | +$1.07B | ||
| 2016 | $7.40B | +13.3% | +$866.69M | ||
| 2015 | $6.53B | +9.3% | +$554.30M | ||
| 2014 | $5.98B | +16.4% | +$842.83M | ||
| 2013 | $5.13B | +15.9% | +$703.51M | ||
| 2012 | $4.43B | -6.8% | −$323.13M | ||
| 2011 | $4.75B | +8.3% | +$363.82M | ||
| 2010 | $4.39B | +19.9% | +$729.19M | ||
| 2009 | $3.66B | +10.3% | +$342.24M | ||
| 2008 | $3.32B | +8.8% | +$267.68M | ||
| 2007 | $3.05B | +18.3% | +$470.81M | ||
| 2006 | $2.58B | +13.5% | +$306.88M | ||
| 2005 | $2.27B | +13.1% | +$262.92M | ||
| 2004 | $2.01B | +29.2% | +$453.33M | ||
| 2003 | $1.56B | — | — | ||
| 2002 | — | — | — | ||
| 2001 | — | — | — | ||
| 2000 | — | — | — | ||
| 1999 | — | — | — | ||
| 1998 | — | — | — | ||
| 1997 | — | — | — | ||
| 1996 | — | — | — | ||
| 1995 | — | — | — | ||
| 1994 | — | — | — | ||
| 1993 | — | — | — | ||
| 1992 | — | — | — | ||
| 1991 | — | — | — | ||
| 1990 | — | — | — | ||
| 1989 | — | — | — | ||
| 1988 | — | — | — | ||
| 1987 | — | — | — | ||
| 1986 | — | — | — | ||
| 1985 | — | — | — |
- 2025$54.86B+22.6%
- 2024$44.75B+45.4%
- 2023$30.79B+35.5%
- 2022$22.72B+20.0%
- 2021$18.93B+759.7%
- 2020$2.20B+43.6%
- 2019$1.53B-83.1%
- 2018$9.05B+6.9%
- 2017$8.47B+14.5%
- 2016$7.40B+13.3%
- 2015$6.53B+9.3%
- 2014$5.98B+16.4%
- 2013$5.13B+15.9%
- 2012$4.43B-6.8%
- 2011$4.75B+8.3%
- 2010$4.39B+19.9%
- 2009$3.66B+10.3%
- 2008$3.32B+8.8%
- 2007$3.05B+18.3%
- 2006$2.58B+13.5%
- 2005$2.27B+13.1%
- 2004$2.01B+29.2%
- 2003$1.56B—
- 2002——
- 2001——
- 2000——
- 1999——
- 1998——
- 1997——
- 1996——
- 1995——
- 1994——
- 1993——
- 1992——
- 1991——
- 1990——
- 1989——
- 1988——
- 1987——
- 1986——
- 1985——
Total Liabilities values are taken from Novo Nordisk's reported balance sheets (interim 6-K and annual 20-F filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts converted to USD using IAS 21 average exchange rates (P&L / cash flow) or closing rates (balance sheet). Originally filed in DKK.
About Total Liabilities at Novo Nordisk (NVO)
According to Novo Nordisk's latest reported financial statements, the company's latest reported total liabilities is $55.08B. Total liabilities sum everything the company owes at the end of each reporting period — accounts payable, accrued expenses, debt, lease obligations, and other claims — as filed on the balance sheet. Compare with total assets and total equity for solvency context.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
2025's annual total liabilities for Novo Nordisk (NVO) came in at 348.86B DKK – grew 8.2% year-over-year.
Novo Nordisk total liabilities compound annual growth for the 2020–2025 (5 years) window is +91.9%, with mixed annual results across the window.
348.86B DKK stands as the all-time-high annual total liabilities, posted in 2025, against a low of 2.45B DKK during 1985.
Novo Nordisk Total Liabilities by Year
Novo Nordisk Total Liabilities 2025: $54.86B
2025's total liabilities for Novo Nordisk came in at 348.86B DKK ($54.86B), grew 8.2% from 2024. This figure represents the highest annual value in the available history.
Novo Nordisk Total Liabilities 2024: $44.75B
Novo Nordisk posted total liabilities of 322.31B DKK ($44.75B) in 2024, surged 55.0% from 2023.
Novo Nordisk Total Liabilities 2023: $30.79B
In 2023, Novo Nordisk reported total liabilities of 207.93B DKK ($30.79B), surged 31.8% from 2022.
Novo Nordisk Total Liabilities 2022: $22.72B
Novo Nordisk total liabilities in 2022 was 157.77B DKK ($22.72B), grew 27.5% from 2021.
Novo Nordisk Total Liabilities 2021: $18.93B
Novo Nordisk total liabilities in 2021 was 123.76B DKK ($18.93B).
See more financial history for Novo Nordisk (NVO).
Sector peers by Total Liabilities
Healthcare peers of Novo Nordisk (NVO), ranked by their latest total liabilities
| $207.88B | |
| $137.19B | |
| $117.67B | |
| $85.94B | |
| $84.20B | |
| $81.93B | |
| $65.36B | |
| $56.81B |
- $207.88B
- $137.19B
- $117.67B
- $85.94B
- $84.20B
- $81.93B
- $65.36B
Frequently asked questions
Novo Nordisk (NVO) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation